Background: Low‐titer group O whole blood (LTOWB) use is increasing due to data suggesting improved outcomes and safety. One barrier to use is low availability of RhD‐negative LTOWB. This survey examined US hospital policies regarding the selection of RhD type of blood products in bleeding emergencies.Study Design and Methods: A web‐based survey of blood bank directors was conducted to determine their hospital's RhD‐type selection policies for blood issued for massive bleeding.Results: There was a 61% response rate (101/157) and of those responses, 95 were complete.Respondents indicated that 40% (38/95) use only red blood cells (RBCs) and 60% (57/95) use LTOWB. For hospitals that issue LTOWB (N = 57), 67% are supplied only with RhD‐positive, 2% only with RhD‐negative, and 32% with both RhD‐positive and RhD‐negative LTOWB. At sites using LTOWB, RhD‐negative LTOWB is used exclusively or preferentially more commonly in adult females of childbearing potential (FCP) (46%) and pediatric FCP (55%) than in men (4%) and boys (24%). RhD‐positive LTOWB is used exclusively or preferentially more commonly in men (94%) and boys (54%) than in adult FCP (40%) or pediatric FCP (21%). At sites using LTOWB, it is not permitted for adult FCPs at 12%, pediatric FCP at 21.4%, and boys at 17.1%.Conclusion: Hospitals prefer issuing RhD‐negative LTOWB for females although they are often ineligible to receive RhD‐negative LTOWB due to supply constraints. The risk and benefits of LTOWB compared to the rare occurrence of hemolytic disease of the fetus/newborn (HDFN) need further examination in the context of withholding a therapy for females that has the potential for improved outcomes.
7 December 2024 in Trauma Surgery & Acute Care Open
Background: The use of low titer group O whole blood (LTOWB) for resuscitation of patients with traumatic hemorrhage is becoming increasingly common. Practices regarding the administration of RhD-positive LTOWB to childbearing age females (CBAFs) vary between institutions due to concerns about RhD alloimmunization. This study examined practices related to LTOWB transfusion as they pertain to age and sex. Methods: This was a secondary analysis of the Shock, Whole blood, and Assessment of TBI (traumatic brain injury) trial, a prospective, multicenter observational cohort study where outcomes following LTOWB transfusion were analyzed at seven level 1 trauma centers between 2018 and 2021, as well as a survey on transfusion practices at these centers conducted in 2023. The proportion of patients who received LTOWB or components was examined over the course of the study and grouped by age and sex, and the RhD group of injured CBAFs was documented. Results: A total of 1046 patients were evaluated: 130 females aged <50 years (CBAFs), 77 females aged ≥50 years; 661 males aged <50 years, and 178 males aged ≥50 years. Among them, 26.2% of CBAFs received RhD-positive LTOWB, whereas 57.1%–66.3% of other sex/age groups received LTOWB. The proportion of CBAFs who received LTOWB increased significantly throughout the 4 years of this study. Except for older women in years 2 and 4, CBAFs were significantly less likely to receive LTOWB than all other groups for the study period and individual years. Among the 33 CBAFs who received LTOWB and for whom an RhD type was available, 4/33 (12.1%) were RhD-negative, while 9/95 (9.5%) CBAFs who received component therapy were RhD-negative. RhD blood product selection practices varied considerably between institutions. Conclusions: Many institutions transfused LTOWB to CBAFs. Policies regarding RhD product selection varied. Of the total cohort, the proportion of RhD-negative CBAFs who received LTOWB increased over time but remained lower than all other groups. Level of evidence: 3.
Background: Low‐titer O whole blood (LTOWB) is commonly used in the United States for severe bleeding. Our objective was to examine disparities in LTOWB utilization and its association with survival.Study Design and Methods: This retrospective analysis included patients receiving at least 1 L of red blood cells (RBC) or LTOWB in the first 4 h of admission. Analyses were stratified by sex and age (<50 years “younger” and ≥50 years “older”). Adjusted analyses for the receipt of LTOWB and 24‐h mortality were performed. Causal mediation analysis assessed whether the ratio of LTOWB to total transfused volume mediated associations with mortality.Results: The younger cohort included 21,192 females and 75,517 males, and the older cohort included 19,761 females and 40,924 males. Upon adjusted analyses, younger and older females were less likely to receive LTOWB OR (95% confidence interval [CI]), 0.61 (0.58–0.64) and OR 0.83 (0.76–0.87), respectively. Increased ratio of LTOWB to total transfused volume was independently associated with reduced mortality in males and females in both young and older cohorts, OR 0.81 (0.74–0.89) and OR 0.74 (0.66–0.83), respectively. Older females had an increased risk of mortality compared with males, OR 1.18 (1.09–1.28). Causal mediation analysis indicated a negligible influence of LTOWB:TTV ratio on the associations between patient sex and mortality (0.11% younger; 0.02% older cohorts).Conclusion: Significant sex‐based disparities exist in LTOWB utilization among severely injured trauma patients. Higher LTOWB ratios are associated with reduced mortality in both females and males. Females above 50 are at increased risk of mortality unrelated to the LTOWB ratio administered.
Background: Use of low titer group O whole blood (LTOWB) continues to increase in the United States (US). This survey sampled the quality control (QC) practices among the largest blood collectors in the US. Methods: A survey on LTOWB collection, QC testing, and distribution was developed and electronically distributed to the chief medical officers of 16 large blood collectors in the US. Only complete survey responses were included. Results: The response rate was 10/16 (63%) representing approximately 80% of the US blood supply as estimated by the respondents. All of the respondents collected LTOWB from males and 7/10 (70%) also collected from never pregnant females. Eight out of nine (89%) centers that repeat donor anti‐A and ‐B titer testing do so on every donation, with 1/9 (11%) respondent testing previously low titer donors annually. The most common antibody titer threshold that defined low titer was <200 (6/10, 60%). The most common LTOWB collection method was with a platelet‐sparing filter in CPD 5/10 (50%). 7/10 (70%) respondents performed QC testing on LTOWB units; all of these respondents collected leukoreduced LTOWB and performed residual leukocyte count testing following leukoreduction. 6/7 (86%) performed residual red blood cell (RBC) recovery counts in the laboratory, 4/7 (57%) measured the unit's weight/volume, while 1/7 (14%) center measured the time taken for leukoreduction. The most often frequency of QC testing was monthly. Conclusion: Current practice at US blood suppliers for QC testing on LTOWB units was limited primarily to testing associated with leukoreduction and RBC counting.